Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie Ready To Leverage Migraine Franchise In Crowded Market

Qulipta Adds Indication Not Covered By Botox, Ubrelvy

Executive Summary

The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.

You may also be interested in...



Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase

Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.

AbbVie Qulipta Shows Benefit In Severely Afflicted Chronic Migraine Patients

The drug could see a competitive edge over other anti-CGRP agents with new chronic migraine data plus convenience as an oral drug and potential for combination with Botox.

Amgen Revenue Boosted By COVID-19 Manufacturing, Flat To Down Without It

The company reported $6.8bn in fourth quarter revenue, missing analyst consensus of $6.9bn even with revenue from supplying Lilly’s COVID-19 antibodies. Enbrel and Aimovig fell by double digits. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel